US · VTRS
Viatris Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Canonsburg, PA 15317
- Website
- viatris.com
Price · as of 2025-12-31
$15.04
Market cap 17.2B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $23.11 | +53.66% |
| Intrinsic Value(DCF) | $6.28 | -58.24% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $18.78 | $34.50 | $0.57 | $6.17 | $24.91 |
| 2012 | $25.12 | $39.42 | $0.33 | $7.30 | $28.49 |
| 2013 | $44.84 | $45.68 | $0.38 | $4.36 | $15.27 |
| 2014 | $45.32 | $43.11 | $0.94 | $9.70 | $45.44 |
| 2015 | $39.73 | $46.04 | $3.32 | $17.34 | $50.04 |
| 2016 | $35.48 | $43.21 | $0.76 | $8.23 | $22.85 |
| 2017 | $34.75 | $42.73 | $0.00 | $12.29 | $20.02 |
| 2018 | $21.75 | $38.88 | $0.00 | $8.10 | $2.94 |
| 2019 | $12.59 | $37.13 | $0.00 | $4.25 | $0.26 |
| 2020 | $11.74 | $33.92 | $0.00 | $12.07 | $0.00 |
| 2021 | $8.45 | $28.48 | $10.29 | $0.00 | $0.00 |
| 2022 | $8.72 | $25.22 | $0.00 | $10.16 | $0.00 |
| 2023 | $11.21 | $24.01 | $0.00 | $1.87 | $0.14 |
| 2024 | $9.18 | $22.96 | $0.00 | $0.00 | $0.00 |
| 2025 | $15.70 | $23.11 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Viatris Inc.'s (VTRS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $23.11
- Current price
- $15.04
- AI upside
- +53.66%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$6.28
-58.24% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| VTRS | Viatris Inc. | $15.04 | 17.2B | +54% | -58% | — | — | -5.23 | 1.25 | 1.29 | -79.59 | -1.12 | -2.57 | 35.06% | -18.62% | -24.58% | -21.08% | -8.56% | -8.93% | 0.98 | -5.65 | 5.06 | 2.25 | -33.11 | 46604.00% | -298.00% | -201.00% | 10.54% | 1.20 | 6.49% | 3.05% | -16.00% | 8.39% | -11.82 | 16.25 | 2.20 | 0.88 |
| BAX | Baxter International Inc. | $20.37 | 10.48B | +17% | -61% | — | — | -10.55 | 1.65 | 0.90 | 23.68 | -27.93 | -3.19 | 30.05% | -2.74% | -8.51% | -14.62% | -1.88% | -4.18% | 1.63 | -1.06 | 2.31 | 1.31 | 10.49 | 3780.00% | 572.00% | -4222.00% | 3.20% | 0.28 | 1.97% | 3.45% | -36.40% | 39.56% | -58.89 | 56.15 | 1.61 | 2.13 |
| BBIO | BridgeBio Pharma, Inc. | $66.48 | 12.89B | -12% | +7,582% | — | — | -17.82 | -6.22 | 25.73 | -22.38 | -56.40 | -6.14 | 94.37% | -113.35% | -145.26% | 40.90% | 321.74% | -78.14% | -1.31 | -10.72 | 2.62 | 2.52 | -3.21 | 3160.00% | 12626.00% | -1431.00% | -3.46% | -1.55 | 252.72% | 0.00% | 0.00% | 0.37% | -26.46 | -33.69 | 30.00 | -4.02 |
| ELAN | Elanco Animal Health Inco… | $26.40 | 13.12B | +23% | -60% | -95% | — | -55.82 | 1.98 | 2.75 | 24.29 | — | -7.90 | 43.48% | 5.34% | -4.92% | -3.67% | 2.52% | -1.79% | 0.61 | 1.15 | 2.17 | 0.93 | 5.14 | -16912.00% | 622.00% | -2792.00% | 2.19% | 0.35 | 2.84% | 0.00% | 0.00% | 2.94% | 65.17 | 57.83 | 3.48 | 1.49 |
| EXAS | Exact Sciences Corporatio… | $103.38 | 19.73B | -34% | -59% | — | — | -93.78 | 8.12 | 6.01 | 171.91 | — | -21.99 | 69.69% | -3.05% | -6.40% | -8.66% | -2.45% | -3.53% | 1.05 | -3.01 | 2.43 | 1.97 | 12.79 | -8032.00% | 1769.00% | 37860.00% | 1.83% | 0.77 | 8.83% | 0.00% | 0.00% | 3.01% | -212.55 | 59.02 | 6.49 | 2.94 |
| IONS | Ionis Pharmaceuticals, In… | $81.15 | 13.14B | -40% | -60% | — | — | -34.38 | 26.82 | 13.89 | -46.25 | — | 26.82 | 98.31% | -40.47% | -40.36% | -70.80% | -221.28% | -11.69% | 5.78 | -5.23 | 1.95 | 1.79 | -8.56 | -2171.00% | 3387.00% | -4141.00% | -2.44% | -0.18 | -185.38% | 0.00% | 0.00% | 0.00% | -34.72 | -41.44 | 14.05 | 1.95 |
| MRNA | Moderna, Inc. | $53.57 | 20.93B | -39% | -52% | — | +298% | -7.28 | 2.38 | 10.57 | -6.53 | — | 2.38 | 55.35% | -158.13% | -145.16% | -28.87% | -65.47% | -21.31% | 0.22 | — | 3.29 | 3.01 | 0.27 | -2168.00% | -3923.00% | -4908.00% | -10.05% | -0.94 | -43.98% | 0.00% | 0.00% | 0.00% | -5.42 | -8.07 | 8.58 | 3.94 |
| NBIX | Neurocrine Biosciences, I… | $132.25 | 13.27B | +32% | +46% | -57% | +4% | 27.52 | 4.05 | 4.60 | 18.16 | 65.61 | 4.05 | 98.18% | 21.64% | 16.73% | 16.38% | 20.21% | 11.46% | 0.13 | — | 3.39 | 2.92 | -0.45 | 4195.00% | 2145.00% | 3437.00% | 5.68% | 1.05 | 36.02% | 0.00% | 0.00% | 5.22% | 19.56 | 16.17 | 4.23 | 7.39 |
| RDY | Dr. Reddy's Laboratories … | $14.38 | 11.97B | -27% | +23% | -53% | +28% | 19.94 | 3.42 | 3.51 | 11.69 | 1373.07 | 5.08 | 58.50% | 22.07% | 17.37% | 18.65% | 19.79% | 13.00% | 0.14 | 25.40 | 1.92 | 1.29 | 0.33 | 145.00% | 1661.00% | -3316.00% | 1.05% | 0.36 | 4.44% | 0.58% | 11.60% | 0.71% | 15.73 | 93.95 | 3.47 | 6.72 |
| RGC | Regencell Bioscience Hold… | $26.23 | 12.97B | — | — | — | — | -1829.39 | 1349.09 | — | -2053.15 | — | 1349.09 | 0.00% | — | — | -54.81% | -886.14% | -50.50% | 0.11 | — | 7.39 | 7.38 | 0.59 | -1724.00% | — | -1849.00% | -0.05% | -4.69 | -767.74% | 0.00% | 0.00% | 0.00% | -1738.09 | -2006.13 | — | 4386.78 |
| ROIV | Roivant Sciences Ltd. | $28.94 | 20.71B | +3% | -75% | -82% | -98% | -22.84 | 1.74 | 280.39 | -3.06 | — | 1.74 | 96.86% | -3453.32% | -591.96% | -6.70% | 1167.58% | -5.64% | 0.02 | — | 33.47 | 32.71 | 2.38 | -10459.00% | -1119.00% | 1010.00% | -10.36% | -5.62 | 982.26% | 0.00% | 0.00% | 15.88% | -3.35 | -3.98 | 115.63 | 20.07 |
About Viatris Inc.
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
- CEO
- Scott Andrew Smith
- Employees
- 32K
- Beta
- 0.80
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($6.28 ÷ $15.04) − 1 = -58.24% (DCF, example).